P-031

P-031 is a pipeline candidate being developed by Pangea Pharmaceuticals for the treatment of epilepsy and seizures. Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development of reformulated or generic versions of existing medications, often utilizing the 505(b)(2) regulatory pathway to improve upon existing therapies. While the specific active ingredient and mechanism of action for P-031 have not been publicly disclosed, the drug is part of Pangea's pipeline of products aimed at addressing neurological conditions. As a product from a company specializing in reformulations, it is likely a new dosage form or delivery method of a known anti-epileptic agent.